Publikationen 2016

Aschermann S, Englbrecht M, Bergua A, Spriewald BM, Said-Nahal R, Breban M, Schett G, Rech J: (2016) Presence of HLA-B27 is associated with changes of serum levels of mediators of the Wnt and hedgehog pathway. Joint Bone Spine. 2016;83(1): 43-6
Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G, Study Alliance Leukemia: (2016) Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. Biol Blood Marrow Transplant. 2016;22(3): 462-9
Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Krämer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J: (2016) Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016;30(2): 261-267
Zimmermann HW, Bruns T, Weston CJ, Curbishley SM, Liaskou E, Li KK, Resheq YJ, Badenhorst PW, Adams DH: (2016) Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver. Hepatology. 2016;63(1): 233-46
Grajewski RS, Bosch JJ, Bruns H, Cursiefen C, Heindl LM: (2016) The Trojan Horse Tale Revisited: An Eye on Metastatic Spread of Carcinoma Cells. Cancer Immunol Res. 2016;4(2): 92-94
Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U: (2016) Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia. Leukemia. 2016;30(3): 555-61
Jacobi J, Beckmann S, Heller K, Hilgers KF, Apel H, Spriewald B, Eckardt KU, Amann KU: (2016) Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program (ESP): A Single-Center Experience from 2008 to 2013. Ann Transplant. 2016;21(): 94-104
Böttcher M, D Hofmann A, Bruns H, Haibach M, Loschinski R, Saul D, Mackensen A, Le Blanc K, Jitschin R, Mougiakakos D: (2016) Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. Stem Cells. 2016;34(2): 516-21
Stölzel F, Mohr B, Krämer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G: (2016) Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J. 2016;6(): e386
Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, Witt K, Lladser A, Chmielewski M, Riet T, Abken H, Kiessling R: (2016) Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity. J Immunol. 2016;196(2): 759-66
Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S: (2016) Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30(6): 1255-62
Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J, Study Alliance Leukaemia (SAL): (2016) TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016;172(6): 914-22
Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC: (2016) Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J Clin Oncol. 2016;34(10): 1104-11
Braun M, Qorraj M, Büttner M, Klein FA, Saul D, Aigner M, Huber W, Mackensen A, Jitschin R, Mougiakakos D: (2016) CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. Leukemia. 2016;30(8): 1788-92
Chevalier N, Mueller M, Mougiakakos D, Ihorst G, Marks R, Schmitt-Graeff A, Veelken H: (2016) Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment. Leuk Lymphoma. 2016;57(9): 2150-60
Weidner CI, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, Bruns H, Balabanov S, Trummer A, Stockklausner C, Höchsmann B, Schrezenmeier H, Wlodarski M, Panse J, Brümmendorf TH, Beier F, Wagner W: (2016) DNA methylation in PRDM8 is indicative for dyskeratosis congenita. Oncotarget. 2016;7(10): 10765-72
Steiger J, Stephan A, Inkeles MS, Realegeno S, Bruns H, Kröll P, de Castro Kroner J, Sommer A, Batinica M, Pitzler L, Kalscheuer R, Hartmann P, Plum G, Stenger S, Pellegrini M, Brachvogel B, Modlin RL, Fabri M: (2016) Imatinib Triggers Phagolysosome Acidification and Antimicrobial Activity against Mycobacterium bovis Bacille Calmette-Guérin in Glucocorticoid-Treated Human Macrophages. J Immunol. 2016;197(1): 222-32
Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, de Boer HC, Jager MJ, Schmelzer E, Vries RG, Al Hinai AS, Kroes WG, Monajemi R, Goeman JJ, Böhringer S, Marijt WA, Falkenburg JH, Griffioen M: (2016) Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies. PLoS ONE. 2016;11(5): e0155165
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G, International Extranodal Lymphoma Study Group (IELSG): (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5): e217-27
Sikic D, Meidenbauer N, Lieb V, Keck B: (2016) [Side effect management of tyrosine kinase inhibitors in urology : Hypertension]. Urologe A. 2016;55(7): 952-5
Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T: (2016) Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2016;34(21): 2484-92
Völkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, Klemann C, Fuchs I, Schuster V, von Bueren AO, Naumann-Bartsch N, Gambineri E, Siepermann K, Kobbe R, Nathrath M, Arkwright PD, Miano M, Stachel KD, Metzler M, Schwarz K, Kremer AN, Speckmann C, Ehl S, Mackensen A: (2016) Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128(2): 227-38
Schleicher U, Paduch K, Debus A, Obermeyer S, König T, Kling JC, Ribechini E, Dudziak D, Mougiakakos D, Murray PJ, Ostuni R, Körner H, Bogdan C: (2016) TNF-Mediated Restriction of Arginase 1 Expression in Myeloid Cells Triggers Type 2 NO Synthase Activity at the Site of Infection. Cell Rep. 2016;15(5): 1062-75
Boch T, Spiess B, Cornely OA, Vehreschild JJ, Rath PM, Steinmann J, Heinz WJ, Hahn J, Krause SW, Kiehl MG, Egerer G, Liebregts T, Koldehoff M, Klein M, Nolte F, Mueller MC, Merker N, Will S, Mossner M, Popp H, Hofmann WK, Reinwald M, Buchheidt D: (2016) Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-?-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of Clin Microbiol Infect. 2016;22(10): 862-868
Wilhelm A, Shepherd EL, Amatucci A, Munir M, Reynolds G, Humphreys E, Resheq Y, Adams DH, Hübscher S, Burkly LC, Weston CJ, Afford SC: (2016) Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. J Pathol. 2016;239(1): 109-21
Gerstner S, Köhler W, Heidkamp G, Purbojo A, Uchida S, Ekici AB, Heger L, Luetke-Eversloh M, Schubert R, Bader P, Klingebiel T, Koehl U, Mackensen A, Romagnani C, Cesnjevar R, Dudziak D, Ullrich E: (2016) Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus. J Leukoc Biol. 2016;100(6): 1297-1310
Finkel P, Frey B, Mayer F, Bösl K, Werthmöller N, Mackensen A, Gaipl US, Ullrich E: (2016) The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology. 2016;5(6): e1101206
Henrich FC, Singer K, Poller K, Bernhardt L, Strobl CD, Limm K, Ritter AP, Gottfried E, Völkl S, Jacobs B, Peter K, Mougiakakos D, Dettmer K, Oefner PJ, Bosserhoff AK, Kreutz MP, Aigner M, Mackensen A: (2016) Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells. Oncoimmunology. 2016;5(8): e1184802
Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M: (2016) LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016;24(5): 657-671
Heidkamp GF, Sander J, Lehmann CHK, Heger L, Eissing N, Baranska A, Lühr JJ, Hoffmann A, Reimer KC, Lux A, Söder S, Hartmann A, Zenk J, Ulas T, McGovern N, Alexiou C, Spriewald B, Mackensen A, Schuler G, Schauf B, Forster A, Repp R, Fasching PA, Purbojo A, Cesnjevar R, Ullrich E, Ginhoux F, Schlitzer A, Nimmerjahn F, Schultze JL, Dudziak D: (2016) Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Sci Immunol. 2016;1(6):
Steven A, Leisz S, Sychra K, Hiebl B, Wickenhauser C, Mougiakakos D, Kiessling R, Denkert C, Seliger B: (2016) Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization Oncotarget. 2016;7(32): 52061-52084

Schriftgröße anpassen

Publikationen 2016

Publikationen 2016

Notfall

Notfallinformationen UKER

Patienten & Besucher

Ärzte & Zuweiser

Forschung

Lehre